Fulcrum Therapeutics Stock Forecast

Stock Price Forecast

According to 9 analysts polled by S&P Global, Fulcrum Therapeutics stock has a consensus rating of "Hold" and an average price target of $6.63. The average 1-year stock price forecast is 79.19% higher than the current stock price, while the lowest is $3.00 (-18.92%) and the highest is $18 (+386.49%).

Price Target: $6.63 (+79.19%)

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	$3.00	$6.63	$3.50	$18
Change	-18.92%	+79.19%	-5.41%	+386.49%

Analyst Ratings

The average analyst rating for Fulcrum Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	6	6	6	6	6	1
Buy	2	2	2	2	2	0
Hold	1	1	1	1	1	5
Sell	1	1	1	1	1	3
Strong Sell	0	0	0	0	0	0
Total	10	10	10	10	10	9

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Anupam Rama J.P. Morgan	J.P. Morgan	Sell Downgrades n/a	Sell	Downgrades	n/a	n/a	Jun 2, 2026
Tazeen Ahmad Bank of America Securities	Bank of America Securities	Sell Maintains $8 → $3	Sell	Maintains	$8 → $3	-18.92%	Jun 2, 2026
Andrew Fein H.C. Wainwright	H.C. Wainwright	Hold Downgrades $25 → $3	Hold	Downgrades	$25 → $3	-18.92%	Jun 2, 2026
Joseph Schwartz Leerink Partners	Leerink Partners	Hold Downgrades $24 → $4	Hold	Downgrades	$24 → $4	+8.11%	Jun 2, 2026
Gregory Renza Truist Financial	Truist Financial	Hold Downgrades $17 → $4	Hold	Downgrades	$17 → $4	+8.11%	Jun 2, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-0.82

from -1.18

EPS Next Year

-0.66

from -0.82

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	19.16M	6.34M	2.81M	80.00M	-	-
Operating Income	-81.05M	-112.13M	-110.66M	-19.83M	-84.77M	-74.15M
Net Income	-80.85M	-109.87M	-97.34M	-9.73M	-74.88M	-63.38M
EPS	-	-	-	-	-1.18	-0.82
Free Cash Flow	-47.54M	-58.12M	-56.72M	-2.08M	-33.92M	-56.32M
No. Analysts	-	-	-	-	-	8

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-0.35
Avg	-0.82
Low	-1.22

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-